Milgamma (Benfotiamine, Cyanocobalamin)

Benfotiamine enters cells easily and is converted to thiamine diphosphate, a cofactor that enhances carbohydrate metabolism and reduces harmful advanced glycation end‑products. Cyanocobalamin provides vitamin B12, which is essential for methionine synthase and methylmalonyl‑CoA mutase activities, supporting DNA synthesis, myelin formation, and overall neuronal health.

The appropriate dose of Milgamma is determined by a qualified healthcare professional based on the individual’s clinical condition, age, weight, and other medications. Patients should follow the prescribing clinician’s instructions and not adjust the dose without medical guidance.

Safety data for Milgamma in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To order Milgamma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements if applicable) and necessary import documentation.

Milgamma combines benfotiamine and cyanocobalamin in a single oral formulation, offering the convenience of a dual‑vitamin approach. Separate B1 and B12 products may require multiple tablets and can differ in bioavailability; benfotiamine’s lipid‑soluble nature often provides superior cellular uptake compared with standard thiamine salts.

Milgamma should be stored at ambient temperature below 25 °C, in its original container, protected from moisture, heat, and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date printed on the packaging.

Milgamma is taken orally, usually with a glass of water. It can be taken with or without food, unless the prescribing clinician advises otherwise. Swallow the tablet whole; do not crush or chew unless instructed by a healthcare professional.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, significant blood‑cell abnormalities, and acute liver injury. Patients should seek immediate medical attention if they experience symptoms like swelling of the face or throat, rash with blistering, unexplained bruising, or jaundice.

Milgamma should be avoided by individuals with known hypersensitivity to benfotiamine, cyanocobalamin, or any excipients in the tablet. It is also contraindicated in patients who have experienced severe allergic reactions to vitamin B1 or B12 preparations. Consultation with a healthcare provider is essential before use in these cases.